| Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data, intelligence platform-based analysis XD Huang, GQ Zhou, JW Lv, HQ Zhou, CW Zhong, CF Wu, ZQ Zheng, ... Radiotherapy and Oncology 129 (2), 389-395, 2018 | 54 | 2018 |
| Thyroid dose‐volume thresholds for the risk of radiation‐related hypothyroidism in nasopharyngeal carcinoma treated with intensity‐modulated radiotherapy—A single‐institution … CL Huang, HW Tan, R Guo, Y Zhang, H Peng, L Peng, AH Lin, YP Mao, ... Cancer medicine 8 (16), 6887-6893, 2019 | 28 | 2019 |
| The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma L Peng, JQ Liu, YP Chen, J Ma The British journal of radiology 92 (1102), 20181031, 2019 | 28 | 2019 |
| The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma L Peng, JQ Liu, C Xu, XD Huang, LL Tang, YP Chen, Y Sun, J Ma Radiation Oncology 14, 1-9, 2019 | 27 | 2019 |
| Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: an updated interpretation L Peng, Y Yang, R Guo, YP Mao, C Xu, YP Chen, Y Sun, J Ma, LL Tang Cancer medicine 7 (12), 5988-5998, 2018 | 21 | 2018 |
| Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort L Peng, C Xu, YP Chen, R Guo, YP Mao, Y Sun, J Ma, LL Tang Oral oncology 89, 102-106, 2019 | 19 | 2019 |
| Optimal modality for detecting distant metastasis in primary nasopharyngeal carcinoma during initial staging: a systemic review and meta-analysis of 1774 patients C Xu, Y Zhang, L Peng, X Liu, WF Li, Y Sun, X Zhang, XP Lin, Q Liu, J Ma Journal of Cancer 8 (7), 1238, 2017 | 17 | 2017 |
| A new model for predicting hypothyroidism after intensity-modulated radiotherapy for nasopharyngeal carcinoma L Peng, YP Mao, CL Huang, R Guo, J Ma, WP Wen, LL Tang Frontiers in oncology 10, 551255, 2020 | 16 | 2020 |
| The efficacy and safety of anti-epidermal growth factor receptor monoclonal antibodies in nasopharyngeal carcinoma: literature-based meta-analyses L Peng, ZL Liu, C Xu, LL Tang, X Liu, AH Lin, Y Sun, YP Chen, J Ma Journal of Cancer 9 (23), 4510, 2018 | 15 | 2018 |
| Necessity of concurrent chemotherapy in N2‐3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of≥ 3 cycles followed by intensity‐modulated radiotherapy H Chang, L Peng, YL Tao, C Chen, WW Xiao, YH Hu, YH Gao Cancer Medicine 8 (6), 2823-2831, 2019 | 14 | 2019 |
| Interleukin-33 modulates immune responses in cutaneous melanoma in a context-specific way L Peng, W Sun, F Wei, L Chen, W Wen Aging (Albany NY) 13 (5), 6740, 2021 | 9 | 2021 |
| The role of Interleukin-33 in Head and Neck squamous cell carcinoma is determined by its Cellular sources in the Tumor Microenvironment L Peng, W Sun, L Chen, WP Wen Frontiers in Oncology 10, 588454, 2021 | 9 | 2021 |
| Treatment effects of cumulative cisplatin dose during radiotherapy following induction chemotherapy in nasopharyngeal carcinoma: propensity score analyses L Peng, JL Chen, GL Zhu, CL Huang, JY Li, J Ma, WP Wen, LL Tang Therapeutic Advances in Medical Oncology 12, 1758835920937424, 2020 | 8 | 2020 |
| A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II–IVa nasopharyngeal carcinoma L Peng, YP Chen, C Xu, LL Tang, L Chen, AH Lin, X Liu, Y Sun, J Ma Oral Oncology 86, 258-265, 2018 | 8 | 2018 |
| The interval between onset and admission predicts disease progression in COVID-19 patients L Peng, QQ Lv, F Yang, XM Wu, CC Zhang, YQ Wang, WH Huang, CW Li, ... Annals of Translational Medicine 9 (3), 2021 | 7 | 2021 |
| Risk factors and characteristics of the recurrence of juvenile nasopharyngeal angiofibroma: a 22-year experience with 123 cases at a tertiary center R Fang, W Sun, J Shi, R Xu, L Peng, Y Lai, F Chen, Y Wen, W Wen, J Li Clinical and Experimental Otorhinolaryngology 15 (4), 364-371, 2022 | 5 | 2022 |
| Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune … GL Zhu, KB Yang, SQ Tang, L Peng Cancer Medicine 10 (23), 8272-8287, 2021 | 5 | 2021 |
| Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials C Xu, S Zhang, Y Zhang, SQ Tang, XL Fang, GL Zhu, L Peng, JQ Liu, ... International Journal of Cancer 149 (1), 108-118, 2021 | 5 | 2021 |
| The survival benefit of lymph node dissection in resected T1–2, cN0 supraglottic cancer: A population‐based propensity score matching analysis R Fang, L Peng, L Chen, J Liao, F Wei, Y Long, W Wen, W Sun Head & Neck 43 (4), 1300-1310, 2021 | 5 | 2021 |
| Socioeconomic status and asthma: A bidirectional Mendelian randomization study L Peng, WP Wen World Allergy Organization Journal 16 (6), 100790, 2023 | 3 | 2023 |
